Breast cancer (BC) is the most frequent type of malignancy in women in both the developed and the developing world[@b1]. It is a heterogeneous disease in regards to its clinical, histological and molecular profile. In recent decades, there has been great progress in the diagnosis of BC, but only oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor2 (Her2) are typically used for BC diagnosis in routine clinical practice. BC intrinsic subtypes, including triple-negative breast cancer (TNBC) and Her2^+^, luminal A, and luminal B BCs, are characterized by immunohistochemistry (IHC) and have important differences in phenotype and prognosis[@b2][@b3]. Inflammation within the breast tumour microenvironment is known to be correlated with increased invasiveness and poor prognosis[@b4]. Pro-inflammatory biomarkers and the immune response are related to BC risk and/or prognosis[@b5][@b6]. However, many cytokines are involved in the pathogenesis of BC, and inflammatory processes and genes involved in cytokine-related functional pathways have gained increasing interest by researchers.

Tumour necrosis factor-α (TNF-α), a multi-functional cytokine, is involved in the promotion of inflammatory responses and plays a critical role in the pathogenesis of inflammatory, autoimmune and malignant diseases[@b7]. TNF-α is also a key molecule in the promotion of angiogenesis through the stimulation of endothelial cell proliferation and the enhancement of the expression of other pro-angiogenic factors[@b8]. Furthermore, TNF-α induces the expression of adhesion molecules involved in the invasion of metastatic tumour cells[@b9][@b10]. Elevated plasma levels of TNF-α have been detected in many malignancies and are often associated with poor prognoses[@b11][@b12][@b13]. Knockdown of the TNF-α gene is associated with cell proliferation inhibition and apoptosis in TNBC[@b14].

Considerable evidence has shown that genetic variations, such as single nucleotide polymorphisms (SNP), in both tumour and host genomes have roles in the diagnosis, treatment outcome and survival of patients with cancer[@b15][@b16]. Increasing evidence has shown that a SNP in the promoter region of the TNF-α gene (−308G \> A, rs1800629) causes genetic susceptibility to many types of tumours and autoimmune diseases, such as hepatocellular carcinoma, myeloma, lymphoma, ulcerative colitis, and Crohn's disease[@b17][@b18][@b19]. The TNF-α-308A allele appears to have higher constitutive and inducible TNF-α expression, as the −308G \> A mutation affects a consensus binding site of AP-2[@b20][@b21]. The association between the TNF-α-308 polymorphism and BC has been widely evaluated in different ethnicities; however, the results of these studies have been inconsistent, possibly due to BC heterogeneity and other factors[@b22]. It is unclear whether TNF-α-308G \> A is associated with different BC subtypes and/or clinical features.

Because TNF-α is tumourigenic *in vitro* and *in vivo*, we hypothesized that the TNF-α-308G \> A polymorphism may have an important function in different BC subtypes and be related to the characteristics of different BC subtypes, especially in highly aggressive BC. The current case-control study investigated the role of TNF-α-308G \> A in BC susceptibility by IHC subtype and ER, PR and Her2 status and the relationship between genotypes and clinicopathological characteristics of BC.

Results
=======

Because the cases and controls were frequency-matched for age, there were no significant differences in the distributions of age between the cases and controls (*P *= 0.275). Of the 768 BC cases, 163 were TNBC and 82 were Her2^+^, 183 were luminal A, 340 were luminal B, 523 were ER^+^, 245 were ER^−^, 585 were PR^−^, and 686 were Her2^−^ BCs. The genotype frequency of TNF-α-308G \> A in the controls was in concordance with Hardy-Weinberg equilibrium (HWE) (*P *= 0.940).

TNF-α-308 polymorphism and BC
-----------------------------

The allelic frequency of TNF-α-308A was 0.074 in the controls and 0.065 in all BC cases. [Table 1](#t1){ref-type="table"} presents the distribution of genotypes for TNF-α-308G \> A in the controls and BC cases. For all BCs, there was no association with the TNF-α-308 polymorphism (OR* *= 0.89, 95% CI: 0.63--1.25, *P *= 0.482) in the dominant genetic model. According to IHC classification, no association was found between the TNF-α-308 polymorphism and the TNBC (OR* *= 0.67, 95% CI: 0.38--1.19, *P *= 0.133), Her2^+^ (OR* *= 0.90, 95% CI: 0.41--1.72, *P *= 0.812), luminal A (OR* *= 0.67, 95% CI: 0.33--1.14, *P *= 0.120) or luminal B (OR* *= 1.20, 95% CI: 0.84--1.77, *P *= 0.523) subtypes. Consistent with the results for all BCs, no association was observed between the TNF-α-308 polymorphism and ER^+^ (OR* *= 0.98, 95% CI: 0.68--1.36, *P *= 0.852), ER^−^ (OR* *= 0.72, 95% CI: 0.43--1.18, *P *= 0.204), PR^−^ (OR* *= 0.92, 95% CI: 0.65--1.34, *P *= 0.867) or Her2^−^ (OR* *= 0.86, 95% CI: 0.63--1.35, *P *= 0.531) BCs.

Due to a lack of information, we conducted an updated meta-analysis to test whether the TNF-α-308 polymorphism is associated with overall BC risk rather than specifically testing its association with the various subtypes. Eighteen studies (including the present study) were included in this analysis, with a total of 13567 BC cases and 15087 controls. The detailed characteristics of each study in the pooled analysis are summarized in [Table 2](#t2){ref-type="table"}. Thirteen studies were conducted in Caucasians[@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35], while the remaining 5 were conducted in Asians[@b36][@b37][@b38][@b39]. No association between the TNF-α-308 polymorphism and BC risk was found in Caucasians (OR* *= 1.06, 95% CI: 0.88--1.27, *P *= 0.555; I^2^* *= 80.7%, *P*~het~ \< 0.001), Asians (OR = 1.07, 95% CI: 0.58--1.96, *P* = 0.826; I^2^ = 88.7%, *P*~het~ \< 0.001) or all subjects (OR* *= 1.04, 95% CI: 0.87--1.24, *P *= 0.653; I^2^* *= 84.6%, *P*~het~ \< 0.001) ([Table 3](#t3){ref-type="table"}). Begg's funnel plot and Egger's test were performed to evaluate the publication bias of all included studies. In the overall analysis, no evidence of obvious asymmetry for the TNF-α-308G \> A polymorphism was found (*P*~Begg's~ = 0.596). Additionally, the Egger's test found no significant publication bias (*P* = 0.375).

TNF-α-308 polymorphism and clinical features of BC
--------------------------------------------------

We analysed the association between TNF-α-308G \> A and clinical characteristics (age at diagnosis, BMI, tumour stage, tumour size, lymph node metastasis, distant metastasis, age at menarche, menopause and family history of cancer) by BC subtypes classified using IHC ([Table 4](#t4){ref-type="table"}). In all BCs, the GA and AA genotypes were less frequent in patients who were 15 years old or more at menarche than inpatients who were under 15 years old at menarche (OR* *= 0.57, 95% CI: 0.35--0.95, *P *= 0.029). In the TNBC group, the GA and AA genotypes were associated with distant tumour metastasis (OR* *= 3.80, 95% CI: 1.31--11.02, *P *= 0.009). After adjusting for tumour size and lymph node metastasis status, this association remained (OR* *= 6.26, 95% CI: 1.88--20.87, *P *= 0.003), and in our study, this association was also statistically significant after adjusting for all clinical characteristics (OR = 5.83, 95% CI: 1.64--20.76, *P *= 0.004).

We analysed the association between TNF-α-308G \> A and clinical characteristics in patients with different ER, PR, and Her2 statuses (Supplementary Table 1). A similar association between the GA and AA genotypes and age at menarche to that observed in all BCs was seen in PR^−^ patients (OR* *= 0.56, 95% CI: 0.32--0.98, *P *= 0.041).

Discussion
==========

Inflammatory cytokines play critical roles at different stages of tumour development and progression, including invasion and metastasis. Although several studies have reported an association between the TNF-α-308G \> A polymorphism and BC risk, the results of those study were inconsistent. Moreover, little is known about this association in the Chinese. In the present study, we found that the TNF-α-308G \> A polymorphism was not associated with the risk of BC in the different IHC subtypes or BCs classified based on ER, PR or Her2 status in Chinese, Asians or Caucasians. We provided evidence that the TNF-α-308 polymorphism is associated with age at menarche in all BCs and in PR^−^ BCs. Interestingly, patients with TNBC and the TNF-α-308A allele had an increased risk of distant tumour metastasis. Our study highlights the effect of the TNF-α gene polymorphism on the progression of BC by subtype. These findings suggest a potential connection between constitutively higher TNF-α expression and the pathogenesis of TNBC.

TNF-α is mainly produced by macrophages and is also expressed in a wide variety of cells, including mast cells, lymphoid cells, endothelial cells, cardiac myocytes, and fibroblasts[@b40]. Two TNF-α bioactive isoforms, a 26-kD transmembrane isoform and a 17-kD soluble isoform that under goes proteolytic cleavage by a metalloprotease, function by binding to TNF-α receptors (TNFRs)[@b41]. Two receptors (TNFR1 and TNFR2) bind TNF-α. TNFR1 is constitutively expressed in most tissues and can be activated by both transmembrane TNF-α (tmTNF-α) and soluble TNF-α (sTNF-α). When the death domain of TNFR1 interacts with the TNF-α receptor-associated death domain (TRADD), the resulting complex recruits proteins to activate apoptosis through caspase-3. TRADD can also bind TNF receptor-associated factor 2 (TRAF2) to recruit proteins that activate inhibitor of nuclear factor kappa-B kinase (IKK), germinal centre kinase (GCK), and receptor-interacting protein (RIP). These molecules then activate the nuclear factor kappa B (NF-κB), c-Jun N-terminal kinase (JNK), and mitogen-activated protein kinase (MAPK) pathways, which promote anti-apoptosis and cell survival. TNFR2 is generally expressed in cells of the immune system and can only bind sTNF-α. TNFR2 lacks a death domain and can also bind TRAF2 to activate an anti-apoptosis pathway[@b42]. Abnormal activation of JNK, MAPK, and NF-κB can lead to the aberrant expression of many genes that cause chronic inflammation, which stimulates tumour growth. Thus, tmTNF-α and sTNF-α act as immunoregulatory cytokines that connect inflammation with cancer progression.

Two recent meta-analyses reported that the TNF-α-308GA and AA genotypes were significantly associated with decreased BC risk in Caucasians[@b22][@b43]. However, the allele frequencies in the controls of some studies[@b44][@b45] included in those two meta-analyses were not in accordance with HWE. Additionally, a meta-analysis by Yang *et al.* included one study that compared the frequencies of the different TNF-α-308 polymorphism genotypes in patients with benign breast disease and controls[@b46] and another study that did not provide the frequencies of each genotype[@b47]. With strict inclusion criteria, we added new individual studies and performed an updated meta-analysis; for all BCs, we found no association with this polymorphism in Asians and Caucasians. It must be noted that BC is a complex disease with multiple environmental and genetic factors contributing to its progression. The lack of an association between TNF-α-308G \> A and all BCs does not indicate that TNF-α-308G \> A has no effect of susceptibility in certain subtypes. Future research is needed to clarify the connection between the higher constitutive TNF-α expression observed with the TNF-α-308G \> A polymorphism and the risk of BC in each BC subtype.

TNBC is frequently observed in young patients and in patients with larger and higher-grade tumours[@b48][@b49]. TNBC is also associated with higher recurrence rates of metastasis and death, especially within 3 years of diagnosis[@b50]. TNBCs must have some specific and common pathways involved in metastasis. Our study provided some clarification of the distinct molecular pathway of distant metastasis in TNBC. It is known that TNF-α is involved in tumour metastasis through the stimulation of chemokines, which increases cell migration and invasion and promotes proliferation, and is involved in angiogenesis by increasing VEGF expression[@b51][@b52]. Our study suggests that higher constitutive TNF-α expression in patients with TNBC rather than other BC subtypes is associated with distant tumour metastasis. Previous studies also support our findings: knockdown of TNF-α gene expression through blockage of the NF-κB pathway inhibited cell proliferation and induced apoptosis in a TNBC cell line[@b14]; and in a murine model of TNBC, targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor 2 suppressed TNBC tumour growth and metastasis[@b53]. Although sTNF-α originates from tmTNF-α, the function of these two isoforms are not exactly the same. Accumulating evidence shows that tmTNF-α might play an opposite role to that of sTNF-α. Tumour cells that express tmTNF-α are protected from apoptosis by the activation of NF-κB by sTNF-α through reverse signalling[@b54]. In tumour cells, the suppression of NF-κB reverse signalling by tmTNF-α resulted in higher cytotoxicity of sTNF-α[@b55]. We propose that higher constitutive TNF-α expression alters the ratio of tmTNF-α to sTNF-α and promotes TNBC cell growth. Future research should focus on how these two isoforms influence BC progression in various subtypes.

The major strengths of this study were the comprehensive analysis of theTNF-α-308 polymorphism in relation to susceptibility for various BC subtypes and its influence on the clinical features of BC, which will greatly help improve our understanding of the role of TNF-α in BC pathogenesis. The modest sample size of each subtype, which caused suboptimal statistical power, is the main limitation of this study; however, this could not be avoided. In conclusion, the present study shows that the TNF-α-308G \> A polymorphism is not associated with BC risk but is associated with distant tumour metastasis in TNBC. This association might be mediated by the constitutively higher expression of tmTNF-α and/or sTNF-α in patients with the TNF-α-308A allele, promoting tumour growth through metastasis. Our results also confirm that targeting TNF-α suppresses TNBC progression.

Patients and Methods
====================

Study subjects
--------------

This case-control study included 768 patients with constitutive BC and 565 cancer-free controls. All subjects were unrelated ethnic Han Chinese women. Patients were recruited from January 2010 to December 2013 at the Cancer Hospital, Shandong Academy of Medical Sciences and Beijing Chao-Yang Hospital, Capital Medical University and had been diagnosed with histologically confirmed BC. In this study, we classified the BC subtypes as TNBC (ER^−^, PR^−^ and Her2^−^), Her2^+^ (ER^−^, PR^−^ and Her2^+^), luminal A(ER^+^, PR^+^ and Her2^−^), and luminal B (ER^+^, PR^−^/PR~low~ and Her2^−^). The controls were randomly selected based on a physical examination in the same region during the same period as patient recruitment. The selection criteria included no history of cancer and frequency matching to cases by age. At recruitment, demographic information and clinical characteristics of each participant were collected. Informed consent was obtained from all participants. This study was conducted in accordance with the approved guidelines of the Institutional Review Board of the Cancer Hospital, Shandong Academy of Medical Sciences and Beijing Chao-Yang Hospital, Capital Medical University.

TNF-α genotyping
----------------

Genomic DNA was extracted from peripheral blood lymphocytes of the study subjects. The genotypes of TNF-α at the -308 (G \> A) site were analysed using a TaqMan genotyping platform (Roche LightCycler 480II, Roche Applied Science). The PCR primers were 5′-GGC CAC TGA CTG ATT TGT GTG T-3′ and 5′-CAA AAG AAA TGG AGG CAA TAG GTT-3′, and the probe sequences were 5′-FAM-CCC GTC CCC ATG CCC CTC-BHQ-3′ and 5′-TET-CTG AAC CCC GTC CTC ATG CCC-BHQ-3′. For quality control, genotyping was performed by researchers blinded to the case or control status, and a 10% random sample of cases and controls was genotyped twice by different persons; the reproducibility was 99.0%.

Meta-analysis
-------------

We used three electronic databases (PubMed, Embase and Web of Knowledge) to identify relevant publications through December 2014 using key words related to the TNF-α gene polymorphism in combination with BC. The literature search was limited to English language publications on human studies. The reference lists of the relevant articles, reviews and editorials were also screened to find all additional eligible studies.

Studies were included in this meta-analysis if they met the following criteria: (1) case-control study design comparing TNF-α-308 polymorphism in BC cases and cancer-free controls; (2) cases were diagnosed histologically; (3)genomic DNA was isolated from peripheral blood leukocytes; (4) the study estimated the association between the TNF-α-308 polymorphism and BC risk; (5) sufficient data existed for calculating odds ratios (ORs) and corresponding 95% confidence intervals (CIs); and (6) the allele frequencies in the control group met HWE. If the same subject group was published in more than one study, the most complete study was selected for this pooled meta-analysis.

All information extracted from the included studies, including the first author, the year of publication, the ethnicity of the subjects, the number of subjects and genotype frequencies in the case and control groups, and the genotyping method, was double-checked and independently extracted from each publication by two investigators. Disagreements were resolved through discussion.

Statistical analysis
--------------------

χ^2^ tests were used to examine the deviation in genotype frequencies from HWE in controls and the differences in demographic variables and genotype distributions for different clinical features of BC. A dominant genetic model was used to estimate the associations between the TNF-α-308 polymorphism and the risk of BC by ORs and 95% CIs, which were calculated by unconditional logistic regression adjusted for age. For the meta-analysis, subgroups of studies based on ethnicity and experimental methods were determined as described in our previous study[@b56]. All statistical analyses were performed using Statistical Analysis System software version 9.2 (SAS Institute, Cary, NC,USA) and Stata 12.0 (StataCorp, College Station, TX, USA). A *P* value less than 0.05 was considered statistically significant.
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###### Genotype distribution of TNF-α-308G \> A in controls and patients with BC.

          Category          GG    GA + AA   OR (95% CI)   *P*                       
  ------------------------ ----- --------- ------------- ------ ------------------- -------
    Controls (n* *= 565)    484    85.7         81        14.3         1.00             
     All BC (n* *= 768)     668    87.0         100       13.0   0.89 (0.63--1.25)   0.482
                                                                                    
        IHC subtype                                                                 
      TNBC (n* *= 163)      147    90.2         16        9.8    0.67 (0.38--1.19)   0.133
     Her2^+^ (n* *= 82)     71     86.6         11        13.4   0.90 (0.41--1.72)   0.812
    Luminal A (n* *= 183)   165    90.2         18        9.8    0.67 (0.33--1.14)   0.120
    Luminal B (n* *= 340)   285    83.8         55        16.2   1.20 (0.84--1.77)   0.523
                                                                                    
      ER and PR status                                                              
      ER^+^ (n* *= 523)     450    86.1         73        13.9   0.98 (0.68--1.36)   0.852
      ER^−^ (n* *= 245)     218    89.0         27        11.0   0.72 (0.43--1.18)   0.204
      PR^−^ (n* *= 585)     503    86.0         82        14.0   0.92 (0.65--1.34)   0.867
     Her2^+^ (n* *= 686)    597    87.0         89        13.0   0.86 (0.63--1.35)   0.531

Data were calculated by logistic regression adjusted for age with the TNF-α-308 variant genotype (GG) as the reference group.

###### Characteristics of studies included in the pooled meta-analysis.

   Ethnicity            Study             Samples (cases/controls)   Genotyping Method   Cases   Controls   *P*~HWE~ (controls)                      
  ----------- -------------------------- -------------------------- ------------------- ------- ---------- --------------------- ------ ------ ----- -------
   Caucasian       Chouchane, 1997                 40/106                  ASPCR          15        24               1             72     33     1    0.183
                    Mestiri, 2001                 243/174                PCR-RFLP         167       53              23            117     53     4    0.480
                    Giordani, 2003                125/100                PCR-RFLP         104       19               2             84     15     1    0.721
                      Azmy, 2004                  705/498                 TaqMan          475      208              22            313    167    18    0.458
               Kamali-Sarvestani, 2005            223/235                 ASO-PCR         192       31               0            203     32     0    0.263
                     Scola, 2006                   84/106                PCR-RFLP         71        12               1             79     26     1    0.472
                     Gaudet, 2007                5156/4983                TaqMan         3679      1345             132           3488   1368   127   0.604
                    Gonullu, 2007                  38/24                 PCRS-SPM         30        6                2             15     9      0    0.258
               Sirotkovic-Skerlev, 2007            158/76                 TaqMan          136       22               0             68     8      0    0.628
                  MARIE-GENICA, 2010             3138/5476             MALDI-TOF MS      2237      822              79            3795   1528   153   0.957
                    Karakus, 2011                 204/204                 ASO-PCR         167       36               1            159     45     0    0.077
                   Madeleine, 2011                869/900              SNPlex system      603      245              21            613    264    23    0.388
               Gómez Flores-Ramos, 2013           465/294                PCR-RFLP         302       96              67            254     38     2    0.660
     Asian            Park, 2002                   95/190                PCR-RFLP         75        20               0            134     54     2    0.174
                     Kohaar, 2009                  40/150                PCR-RFLP         21        16               3            211     24     2    0.170
                     Pooja, 2011                  200/200               Sequencing        179       19               2            166     34     0    0.189
                       Xu, 2014                   1016/806               PCR-RFLP         927       89               0            716     89     1    0.300
                      This study                  768/565                 TaqMan          668       97               3            484     78     3    0.940

ASPCR: allelic specific polymerase chain reaction; ASO-PCR: allele specific oligonucleotide-polymerase chain reaction; MALDI-TOF MS: matrix-assisted laser desorption/ionization time-of flight mass spectrometry; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; PCRS-SPM:polymerase chain reaction sequence-specific primers method; SNPlex system is a genotyping platform of Applied Biosystem.

###### Meta-analysis of the association between the TNF-α-308G \> A polymorphism and BC in Caucasians and Asians (dominant model)

   Ethnicity   Study (n)   Samples (cases/controls)   Cases   Controls   *P*~HWE~ (controls)   OR (95% CI)   *P*    I^2^ (%)   *P*~het~                                     
  ----------- ----------- -------------------------- ------- ---------- --------------------- ------------- ------ ---------- ---------- ------------------- ------- ------ ---------
   Caucasian      13             11448/13176          8178      2919             351              9260       3586     330       0.437     1.06 (0.88--1.27)   0.555   80.7   \<0.001
     Asian         5              2119/1911           1870      241               8               1711       279       8        0.345     1.07 (0.58--1.96)   0.826   88.7   \<0.001
    Overall       18             13567/15087          10048     3160             359              10971      3865     338       0.912     1.04 (0.87--1.24)   0.653   82.7   \<0.001

###### Clinicopathological features of BC patients classified by IHC subtype and TNF-α-308 polymorphism.

        Characteristics        All BC (n* *= 768)   TNBC (n* *= 163)      Her2^+^ (n* *= 82)                                                                                                    
  --------------------------- -------------------- ------------------ --------------------------- ----------- ----- ---- ---------------------------- ----------- ---- ---- ------------------- -------
          Age (years)                                                                                                                                                                           
              ≤45                     369                  43                    1.00                          49    8               1.00                          18   5          1.00             
              \>45                    399                  57              0.89 (0.58--1.37)         0.604     98    8        0.50 (0.18--1.41)          0.184     53   6    0.41 (0.11--1.50)   0.167
                                                                                                                                                                                                
   Body mass index (kg/m^2^)                                                                                                                                                                    
              ≤25                     353                  54                    1.00                          81    13              1.00                          38   5          1.00             
              \>25                    321                  37              0.75 (0.48--1.18)         0.211     72    4        0.35 (0.11--1.11)          0.064     33   6    1.38 (0.39--4.95)   0.618
                                                                                                                                                                                                
         Tumour stage                                                                                                                                                                           
              I+II                    375                  47                    1.00                          80    7               1.00                          31   4          1.00             
             III+IV                   393                  44              1.20 (0.77--1.86)         0.419     67    10       1.71 (0.62--4.73)          0.300     40   7    1.36 (0.36--5.05)   0.649
                                                                                                                                                                                                
       Tumour size (cm)                                                                                                                                                                         
               ≤5                     547                  69                    1.00                          112   14              1.00                          52   6          1.00             
              \>5                      72                  10              1.10 (0.54--2.23)         0.790     17    1        0.47 (0.06--3.81)          0.470     10   1    0.87 (0.09--8.00)   0.900
                                                                                                                                                                                                
     Lymph node metastasis                                                                                                                                                                      
               No                     275                  35                    1.00                          70    6               1.00                          29   5          1.00             
              Yes                     385                  55              1.12 (0.72--1.76)         0.616     79    10       1.48 (0.51--4.27)          0.470     32   6    1.09 (0.30--3.95)   0.898
                                                                                                                                                                                                
      Distant metastasis                                                                                                                                                                        
               No                     617                  74                    1.00                          125   10            **1.00**                        66   11         1.00             
              Yes                      56                  10              1.49 (0.73--3.04)         0.272     23    7    **3.80** (**1.31--11.02)**   **0.009**   5    0           NA              
                                                                                                                                                                                                
    Age at menarche (years)                                                                                                                                                                     
              ≤15                     415                  70                  **1.00**                        103   11              1.00                          39   10         1.00             
              \>15                    228                  22          **0.57** (**0.35--0.95)**   **0.029**   47    5        1.00 (0.71--1.42)          0.995     29   3    0.40 (0.10--1.60)   0.186
                                                                                                                                                                                                
           Menopause                                                                                                                                                                            
              Yes                     423                  54                    1.00                          72    8               1.00                          37   5          1.00             
               No                     224                  33              1.15 (0.73--1.83)         0.543     74    7        0.85 (0.29--2.47)          0.767     31   5    1.19 (0.32--4.51)   0.794
                                                                                                                                                                                                
   Family history of cancer                                                                                                                                                                     
               No                     531                  75                    1.00                          118   11              1.00                          53   10         1.00             
              Yes                     140                  20              1.01 (0.60--1.71)         0.966     30    4        1.43 (0.43--4.81)          0.561     14   3    1.14 (0.28--4.69)   0.860

        Characteristics        Luminal A (n = 183)   Luminal B (n = 340)                                                             
  --------------------------- --------------------- --------------------- ------------------- ------- ----- ---- ------------------- -------
          Age (years)                                                                                                                
              ≤45                      73                     8                  1.00                  129   22         1.00             
              \>45                     92                    10            0.99 (0.37--2.64)   0.987   156   33   1.24 (0.69--2.23)   0.472
                                                                                                                                     
   Body mass index (kg/m^2^)                                                                                                         
              ≤25                      90                    12                  1.00                  144   24         1.00             
              \>25                     75                     6            0.60 (0.22--1.68)   0.326   141   21   0.89 (0.48--1.68)   0.726
                                                                                                                                     
         Tumour stage                                                                                                                
              I+II                     104                   11                  1.00                  160   25         1.00             
             III+IV                    61                     7            1.09 (0.40--2.95)   0.873   125   20   1.02 (0.54--1.93)   0.941
                                                                                                                                     
       Tumour size (cm)                                                                                                              
               ≤5                      136                   17                  1.00                  247   32         1.00             
              \>5                      10                     1            0.80 (0.10--6.64)   0.836   35    7    1.54 (0.63--3.76)   0.336
                                                                                                                                     
     Lymph node metastasis                                                                                                           
               No                      77                     7                  1.00                  99    17         1.00             
              Yes                      88                    11            1.38 (0.51--3.72)   0.529   186   25   1.90 (0.79--4.55)   0.144
                                                                                                                                     
      Distant metastasis                                                                                                             
               No                      153                   17                  1.00                  273   36         1.00             
              Yes                      11                     1            0.82 (0.10--6.73)   0.852   17    2    0.89 (0.20--4.02)   0.882
                                                                                                                                     
    Age at menarche (years)                                                                                                          
              ≤15                      110                   14                  1.00                  163   35         1.00             
              \>15                     53                     4            0.59 (0.19--1.89)   0.372   99    10   0.52 (0.25--1.07)   0.070
                                                                                                                                     
           Menopause                                                                                                                 
              Yes                      99                    11                  1.00                  215   30         1.00             
               No                      51                     7            1.24 (0.45--3.38)   0.680   68    14   1.48 (0.74--2.94)   0.267
                                                                                                                                     
   Family history of cancer                                                                                                          
               No                      117                   15                  1.00                  243   39         1.00             
              Yes                      45                     6            1.04 (0.38--2.85)   0.939   51    7    1.21 (0.51--2.84)   0.513

The total number of individuals may not be the same because of censored data.
